Yeh, Y., Tsai, H., Huang, C., Wang, J., Lin, Y., Tang, H., . . . Wang, J. (2016). Prospective analysis of UGT1A1 promoter polymorphism for irinotecan dose escalation in metastatic colorectal cancer patients treated with bevacizumab plus FOLFIRI as the first-line setting: Study protocol for a randomized controlled trial. Trials.
শিকাগো স্টাইলে সাইটেশনYeh, Yung-Sung, et al. "Prospective Analysis of UGT1A1 Promoter Polymorphism for Irinotecan Dose Escalation in Metastatic Colorectal Cancer Patients Treated With Bevacizumab Plus FOLFIRI As the First-line Setting: Study Protocol for a Randomized Controlled Trial." Trials 2016.
এমএলএ সাইটেশনYeh, Yung-Sung, et al. "Prospective Analysis of UGT1A1 Promoter Polymorphism for Irinotecan Dose Escalation in Metastatic Colorectal Cancer Patients Treated With Bevacizumab Plus FOLFIRI As the First-line Setting: Study Protocol for a Randomized Controlled Trial." Trials 2016.